Natera, Inc. · NASDAQ:NTRA
Natera — 40th Annual J.P. Morgan Healthcare Conference (January 2022)
26 slides from Natera's conference presentation, Jan 10, 2022
Slide 1: Natera, Inc. Investor presentation JPM 2022
Natera, Inc. Investor presentation JPM 2022
Slide 2: Safe harbor statement
Safe harbor statement This presentation contains forward-looking statements under the meaning of the Private Securities Litigation Reform Act of 1995. All statements other than statements of historical facts contained in this presentation, including statements regarding our market opportunity, our p
Slide 3: Leader in cell-free DNA technology
Leader in cell-free DNA technology • >3 million 2013 2020 tests performed Panorama NIPT launch ONCOLOGY • Leader in published data across cell-free DNA applications WOMEN’S HEALTH • 300+ technology patents ORGAN HEALTH filed, >100 issued 3 Not for reproduction or further distribution.
Slide 4: Rapid innovation and growth
Rapid innovation and growth 2009 2021 Women’s Health Oncology ECD Early cancer detection Organ Kidney Lung Health Heart 4 Not for reproduction or further distribution.
Slide 5: Driven by real world data
Driven by real world data Leader in published data across cell-free DNA applications 69+ 15+ 12+ Women’s Health Oncology Organ Health peer-reviewed peer-reviewed peer-reviewed publications publications publications >1.3M patients studied 5 Not for reproduction or further distribution.
Slide 6: Our formula for success
Our formula for success Leading-edge Extreme focus on technology + customer experience constant innovation + support services #1 in clinical Broad + talented data + expert commercial teams clinical teams 6 Not for reproduction or further distribution.
Slide 7: Transformational 2021
Transformational 2021 >1.5M total tests processed; ~52% growth vs 2020 Consolidated market share in women’s health even as the market expanded significantly Raised revenue guide by >$100M through the course of the year Groundbreaking new cancer data: phase 3 data in bladder cancer, landmark
Slide 8: Volume acceleration in 2021
Volume acceleration in 2021 1,800K 1,600K Total processed units (K) >1,500K 1,400K 52% 1,200K 28% 1,027K 1,000K 20% 803K 800K 30% 668K 15% 600K 515K 44% 447K 400K 310K 200K K 2015 2016 2017 2018 2019 2020 2021 8 Not for reproduction or further distribution.
Slide 9: Average risk NIPT will help millions of patients per year
Average risk NIPT will help millions of patients per year ACOG/SMFM support ~4.4M pregnancies in U.S.1 ~3.6M ~0.8M High risk pregnancies Average risk pregnancies Current market adoption 1. CDC, National Vital Statistics Reports Volume 70, Number 2 March 23, 2021. Estimates based on number of pregnan
Slide 10: The value of prenatal screening
The value of prenatal screening Identifies a high-risk cohort of patients who may benefit from diagnostic testing Historical method Natera’s approach Responsible approach: ⎼ NPV and PPV on every report Serum test Panorama test ⎼ Free information sessions with licensed genetic counselor pre Trisomy 2
Slide 11: Not for reproduction or further distribution.
11 Not for reproduction or further distribution.
Slide 12: Definitive SMART trial highlights NIPT accuracy
Definitive SMART trial highlights NIPT accuracy Study results Comments Aneuploidies (Trisomy 21): Clinical utility of testing for 22q: • 99% sensitivity / 99.97% specificity • Avoid diagnostic odyssey: average of 4.7 • Accuracy of 99.97% (results correct 99.97% of time) years to diagnosis • Positive
Slide 13: Transplant: significant opportunity to help patients
Transplant: significant opportunity to help patients Tests per year >1M tests per year ~1.2M < 10% of transplant recipients tested today Heart, lung, other Kidney Total < 10% Source: internal company estimates 13 Not for reproduction or further distribution.
Slide 14: Only Prospera Kidney offers quantification
Only Prospera Kidney offers quantification Factors that may influence total cfDNA1-9 • High body mass index • Infection Absolute quantity of dd-cfDNA • Age (copies per mL) • Surgery % dd- Total quantity of cfDNA = cfDNA • Shipment & storage • Chemotherapy (copies per mL) • Normal variation • Myocard
Slide 15: Initial results from Trifecta study further validates Prospera with quantification
Initial results from Trifecta study further validates Prospera with quantification Largest prospective fully biopsy-matched, multi-site cohort of dd-cfDNA for kidney transplant recipients1 Details of study Initial results: Area under the curve ● More than 300 biopsy-matched samples Rejection from no
Slide 16: Commercial launch of Prospera Heart and Prospera Lung
Commercial launch of Prospera Heart and Prospera Lung Prospera Heart Prospera Lung Heart Transplants/Yr1 3,952 Lung Transplants/Yr1 2,940 Patients living with a transplant2 40,921 Patients living with a transplant2 17,798 Tests per year >190,000 Tests per year >90,000 Area Under the Curve (AUC) 0.84
Slide 17: Expanding Oncology TAM opportunity
Expanding Oncology TAM opportunity ctDNA / liquid biopsy Early detection Monitoring/MRD Therapy selection $30B $15B $6B Source: internal company estimates 17 Not for reproduction or further distribution.
Slide 18: Consistent MRD results validated across multiple tumor types
Consistent MRD results validated across multiple tumor types Positive Signatera result, without further treatment, has predicted relapse with overall PPV > 98%1-4 1. Reinert T, Henriksen TV, Christensen E, et al. Analysis of Plasma Cell-Free DNA by Ultradeep Sequencing in Patients With Stages I to I
Slide 19: Oncology evidence generation advancing
Oncology evidence generation advancing Disease-free survival Overall Prospective survival Sensitivity Outcomes Data Predictive of treatment benefit Specificity Validation Data PPV/NPV 19 Not for reproduction or further distribution.
Slide 20: Circulate-IDEA Japan: largest prospective MRD study
Circulate-IDEA Japan: largest prospective MRD study ASCO, ESMO IO 2021 Upcoming 2022 • ~1200 patients enrolled • ~1600 patients enrolled • ~800 patients analyzed • ~1000 patients analyzed • Disease free survival stratified by • Disease free survival stratified by ctDNA result: ctDNA result: ⎼ Mean ~
Slide 21: Leading in clinical data development
Leading in clinical data development ASCO, ESMO IO 20211 Upcoming 2022 Prognostic Predictive % 100 • Do MRD positive patients benefit from chemotherapy? 80 ⎼ is the benefit present across stages? 60 • Are ctDNA dynamics predictive of adjuvant chemotherapy benefit? 40 ctDNA • Do MRD negative patients
Slide 22: Significant unmet need served by one technology platform and one commercial team
Significant unmet need served by one technology platform and one commercial team Short term eligible population Mid term population Published/presented indications Studies underway ~13M 12 9 Tests per year (M) 6 ~4M 3 0 IO response Adjuvant Ovarian Esophageal monitoring MIBC Stage II-III CRC Neo-adj
Slide 23: Signatera coverage roadmap
Signatera coverage roadmap 2020 – 2021 2022 – 2023 goals 2024 onward • Colorectal, stages II-IV • NCCN guidelines in CRC • Readouts from definitive, • Immunotherapy response • Coverage for 5+ additional phase 3 studies monitoring, pan-cancer cancer types • Pan-cancer coverage • ADLT status from CMS
Slide 24: Pharma business yielding major phase III wins
Pharma business yielding major phase III wins IMvigor 0101 Phase III trials enrolling Why we win 1.00 Zest2 • Phase III trial evaluating • Product performance MRD 0.75 negative niraparib (Zejula) in early- Overall survival stage breast cancer patients • Regulatory capability 0.50 MRD positive Imvigo
Slide 25: Potential 2022 catalysts
Potential 2022 catalysts Continued adoption of NIPT SMART trial publication early 2022 CIRCULATE-IDEA data in colorectal cancer BESPOKE data early readout 2H 2022 Data and publications in multiple different cancer types Additional reimbursement for Signatera in new tumor types Suite of
Slide 26: Natera, Inc.
©2020 Natera, Inc.Inc. All Rights Reserved. NotNot for reproduction or further distribution. 26 Not for reproduction or further distribution. ©2022 Natera, All Rights Reserved. for reproduction or further distribution.
Natera — 40th Annual J.P. Morgan Healthcare Conference (January 2022) on 6ix